Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2025-07-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于全资子公司变更注册地址并完成工商登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of registered address of a wholly-owned subsidiary and completion of related business registration procedures. It includes details about the new address, company registration information, and legal representative. There is no financial data, no mention of financial results, no voting results, no management changes, no legal proceedings, no capital changes, and no other report types. The document is a regulatory announcement about a corporate administrative change. It is short (1063 characters) and does not contain financial statements or detailed reports. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-07-25 Chinese
关于公司股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the release of pledged shares by a significant shareholder of the company. It details the number of shares released from pledge, the shareholder's total holdings, and confirms no adverse conditions such as freezing or auction of shares. There is no financial data, earnings information, or management discussion. The document is a regulatory announcement about share pledge status, which fits the category of Major Shareholding Notification (MRQ) as it involves changes in significant share ownership levels and related disclosures.
2025-07-17 Chinese
第四届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the ninth meeting of the fourth board of directors of the company. It details the meeting date, attendance, and voting results on a specific agenda item related to related-party borrowing. It references another announcement for more details but does not contain financial statements or detailed management discussion. The document is a formal disclosure of board meeting decisions, which fits the category of Board/Management Information (MANG). The document length is short and focused on board decisions, not a full report or financial results.
2025-07-14 Chinese
第四届监事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the ninth meeting of the fourth Supervisory Board of Sailong Pharmaceutical Group Co., Ltd. It includes details about the meeting's convening, attendance, and the approval of a related-party loan transaction. The document references another announcement (2025-042) for details on the related-party loan. The content is about board/committee meeting decisions and approvals rather than a full report or financial statement. It is not an annual report, audit report, earnings release, or any financial report. It is also not a voting result announcement since it is about a board resolution, not shareholder voting. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short and it is a standalone announcement of a board meeting resolution, not a report publication or certification. Confidence is high due to clear meeting and resolution content.
2025-07-14 Chinese
第四届董事会独立董事2025年第二次专门会议的审查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the independent directors of the board regarding a related party transaction and borrowing proposal. It references company law, securities law, stock exchange listing rules, and internal governance guidelines. The content focuses on the board's review and approval process for a specific transaction, including conflict of interest management and fairness assessment. There is no financial data, earnings information, or report publication mentioned. The document is clearly related to board-level governance and management oversight rather than a full annual report, audit report, or earnings release. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management, including approvals of significant transactions.
2025-07-14 Chinese
关于公司向关联方借款暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related party loan transaction between the company and a major shareholder who is also a director and president. It details the loan amount, terms, interest rate, approvals by the board and independent directors, and compliance with stock exchange rules. The document is a formal disclosure of a financing transaction involving related parties, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive transaction details. The content fits the category of Capital/Financing Update (CAP), as it updates on company financing activities and capital structure changes involving related party borrowing.
2025-07-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.